Translate page


Timothy Hughes                            


Deborah White Agnes YONG w labcoat1              


Session 5: The CML frontier
Chair: Dr David Yeung

  • Making TFR Mainstream
    (Prof. Tim Hughes)
  • Prognostic biomarkers in CML
    (Prof. Deborah White)
  • The immunology of CML and immunomodulation
    (A/Prof Agnes Yong)



David Ross


Devendra Hiwase Michael Osborn              


Session 4: CML Related Topics
Chair: A/Prof Agnes Yong

  • Management of Myelofibrosis
    (Dr David Ross)
  • MDS/MPN Overlap Syndrome
    (Dr Devendra Hiwase)
  • Pediatric CML
    (Dr Michael Osborn)



Susan Branford


David Ross David Yeung 3                  


Session 3: TFR in CML
Chair: Dr David Ross

  • Monitoring TFR - Challenges 
    (A/Prof Susan Branford)
  • TFR in CML - Clinical Trial Update
    (Dr David Ross)
  • Response definitions and endpoint determination 
    in CML clinical trials
    (Dr David Yeung)



Susan BranfordAgnes YONG w labcoat1  




Session 2: CML management, Practicalities
Chair: Prof. Tim Hughes

  • Molecular monitoring in CML
    (A/Prof Susan Branford)
  • Allograft - still a role in CML?
    (A/Prof Agnes Yong)


-- Virtual Education Program: 2018 Edition


Presentations from the COLT Meeting 2018

We are pleased to make available a series of presentations from the COLT Meeting 2018, a CML Opinion Leader Training that took place in Adelaide (Australia). Topics cover; CML therapy - state of science, practicalities on CML management, TFR in CML, CML related topics and the CML frontier.

Timothy Hughes.pngDavid Yeung 3Devendra Hiwase



Session 1: CML therapy - state of science
Chair: Prof. Tim Hughes

  • CML - current clinical issues
    and future directions 
    (Prof Tim Hughes)
  • When frontline therapy fails
    (Dr David Yeung)
  • CML - Beyond chronic phase
    (Dr Devendra Hiwase)


Presentations from the 23rd Congress of EHA 

EHA 2018 Réa

TFR - a new treatment goal of CP-CML patients?
Dr Delphine Réa, Centre-Hospitalo-Universitaire Saint-Louis, Paris, France 

  • Lessons from clinical trials: TKI discontinuation in CP-CML is feasible
  • Deep-molecular responses: definitions
  • Clinical practice: patient case
  • Deep-molecular responses during 1st line TKI treatment
  • TKI discontinuation in CP-CML: transition from trials to standard practice
  • TKI withdrawal syndrome during the treatment-free phase
  • Recommendations for standard practice: definitions and management of relapses
  • Conclusion 1: Evolving treatment goals
  • Conclusion 2: TKI discontinuation in standard practice

We are very grateful for the support of Brandcast media to produce these webstreams.